At­las, F-Prime pro­vide launch mon­ey for Akre­via — a lit­tle biotech with big plans to de­sign bet­ter drugs

A cou­ple of vet­er­an drug de­vel­op­ers are guid­ing a stealthy start­up dubbed Akre­via Ther­a­peu­tics out in­to the open to­day af­ter a pair of high-pro­file biotech in­vestors blessed the op­er­a­tion with a $30 mil­lion launch round.

Akre­via is head­ed by sci­en­tist Tim Clack­son, whose last role was run­ning the R&D shop at Ari­ad un­til Take­da came in and bought it, and ex­ec­u­tive chair­man Nes­san Berming­ham, whose last gig was CEO of the gene edit­ing com­pa­ny In­tel­lia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER